PHAR (Pharming Group) Beta: -0.5075 (As of Jun. 25, 2026)


PHAR Pharming Group PHAR
79 GF Score
Price $13.09
GF Value $14.23
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Beta?

Pharming Group PHAR +0.85% 79 Beta is -0.5075 as of Jun. 25, 2026. GuruFocus rates PHAR with a GF Score™ of 79/100 and a GF Value™ of $14.23 (Fairly Valued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Pharming Group's Beta is -0.5075.


Pharming Group  (NAS:PHAR) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Pharming Group Beta Related Terms


Pharming Group Beta Historical Data

* Premium members only.

The historical data trend for Pharming Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Beta Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.21 -0.16 -0.20

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.10 0.29 -0.20 -0.40

PHAR vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Pharming Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Beta distribution charts can be found below:

* The bar in red indicates where Pharming Group's Beta falls into.


PHAR
79GF Score
Pharming Group PHAR
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.5075 mean?
Pharming Group (PHAR) has a Beta of -0.5075 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pharming Group and its competitors.
Is Pharming Group's Beta too high?
Pharming Group's current Beta is -0.5075. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Beta compare to VRTX and REGN?
Pharming Group's Beta of -0.5075 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pharming Group and its competitors. Pharming Group's current Beta is -0.5075. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.23, compared to a current price of $13.09 — trading 8% below its estimated fair value. The current Beta is -0.5075. Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pharming Group (PHAR), the current Beta is -0.5075 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.09 is trading 8% below its estimated GF Value™ of $14.23. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Beta: -0.5075
  • GF Value™: $14.23 vs. price of $13.09 (8% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score

Get the complete analysis for PHAR

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.09
Price
$14.23
GF Value